Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Investigating Mechanisms Behind Early HIV-1 Infection
Scientific Advances

Investigating Mechanisms Behind Early HIV-1 Infection

By Melissa RohmanNov 1, 2021
Share
Facebook Twitter Email
Mojgan Naghavi, PhD, professor of Microbiology-Immunology and a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, was senior author of the study published in Proceedings of the National Academy of Sciences

Northwestern Medicine investigators have discovered that a microtubule regulatory protein inhibits early HIV type 1 (HIV-1) infection, according to findings published in Proceedings of the National Academy of Sciences.

Mojgan Naghavi, PhD, professor of Microbiology-Immunology and a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, was senior author of the study.

Many viruses require the dynein-dynactin motor-adaptor complex, which is responsible for the intracellular transport of cargos along microtubules on a cell’s cytoskeleton to reach the nucleus. Viruses exploit this complex to reach the nucleus and initiate infection.

Many viruses bind directly to microtubule motor proteins to travel within the cell, but previous work has shown that HIV-1 uses different cellular mechanisms to engage motor adaptors indirectly. In addition, unlike many viruses, HIV-1 does not require the protein dynactin-1 (DCTN1) — the core component of dynactin cargo adaptor for dynein— and the significance of this phenomenon has remained unknown, according to the authors.

By analyzing cells infected with HIV-1, Naghavi and colleagues found that DCTN1 inhibits early HIV-1 infection by interfering with the ability of the viral core, or the capsid shell surrounding the genome of the virus, to interact with critical cofactors (non-protein chemicals) within the host cell.

Specifically, DCTN1 competes for binding to HIV-1 particles with the cytoplasmic linker protein 170 (CLIP170), a microtubule plus-end tracking protein (+TIP), that the investigators had previously shown regulates the stability of viral cores after entry into the cell.

Depletion of CLIP170 or DCTN1 in human cells cause only modest decreases in MT dynamic as determined by measuring EB1 comet lengths (green), which track growing MT ends. The nucleus of the human cells are in blue.

In the current study, they discovered that DCTN1 influences infection not as a component of the dynactin complex but instead as a +TIP that binds to and isolates CLIP170 from interacting with incoming HIV-1 particles.

“This negative function of DCTN1 in regulating +TIP functions outside the dynactin complex offers a rationale for why HIV-1 might have evolved away from DCTN1 as a means to engage dynein,” Naghavi said. “Our findings not only provide an explanation as to why HIV-1 has evolved away from using DCTN1 as a motor adaptor, but it also reveals mechanistic insights into the broader functional contributions of +TIPs in controlling HIV-1 infection.”

According to Naghavi, the findings could improve the development of novel therapeutic strategies to treat HIV-1, as current drugs targeting microtubules in cells, such as those currently used in chemotherapy, are toxic.

“More refined drugs targeting highly specialized microtubule regulators could potentially be an attractive approach for development of new, non-toxic therapeutic strategies to treat HIV-1,” Naghavi said.

Jackson Campbell, a sixth-year student in the Driskill Graduate Program in Life Sciences, was a co-author of the study.

This work was supported by National Institutes of Health grants P01GM105536 and R01AI150559.

Immunology Microbiology Research
Share. Facebook Twitter Email

Related Posts

Investigating Protein’s Role in Hearing Loss

Mar 27, 2023

Sex-Specific Mechanisms for Major Depressive Disorder Identified in Response to Dysregulated Stress Hormones

Mar 23, 2023

Pre-Surgery Immunotherapy May Increase Survival in Advanced Melanoma

Mar 23, 2023

Comments are closed.

Latest News

Investigating Protein’s Role in Hearing Loss

Mar 27, 2023

Sex-Specific Mechanisms for Major Depressive Disorder Identified in Response to Dysregulated Stress Hormones

Mar 23, 2023

Pre-Surgery Immunotherapy May Increase Survival in Advanced Melanoma

Mar 23, 2023

Hormone Therapy Plus Current Treatments Improves Survival in Prostate Cancer

Mar 22, 2023

How ChatGPT Has, and Will Continue to, Transform Scientific Research

Mar 21, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20230317_NM651
20230317_NM610
20230317_NM569
20230317_NM537
20230317_NM331
20230317_NM323
20230317_NM316
20230317_NM336
20230317_NM626
20230317_NM662
20230317_NM655
20230317_NM642

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.